Sam-A Pharm. Co. Ltd (009300) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Sam-A Pharm. Co. Ltd stock KRW 23,291, price KRW 12,990, upside +79.3%, quality 58 out of 100. Rating: strongly undervalued. Calculated from audited financials with 24 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 9, 2026.
How to read this chart
60‑month range 11,461 KRW – 32,676 KRW · fair‑value band 16,249 KRW – 31,637 KRW · the 12,990 KRW price screens below the 23,291 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 9, 2026.
Follow Sam-A Pharm. Co. in your weekly email
Every Wednesday you see whether Sam-A Pharm. Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Sam-A Pharm. Co., Ltd operates as a pharmaceutical company in South Korea.
Show moreShow less
The company offers a range of pharmaceutical products in the areas of respiratory, anti-biotics, anti-virals, anti-histamines, anti-fungals, dermatology, pain/inflammation, gastrointestinal, cardiovascular, metabolism, urological, and steroids, as well as psychotropic agents; and OTC products in the areas of respiratory, ant-analgesics, gastro-intestinal, topical, oral, and anti-histamines.
It also provides NOMA MEGAFFECT for stress relief, eye care, memory and blood lipid concentration enhancement, endurance enhancement, and the supply of vitamins and minerals; and NOMA-F gummy, NOMA CHEWABLE tablet, and NOMA GOLD chewable tablet for growth promotion, enhancement of nutritional deficiency, and supply of vitamins.
Sam-A Pharm. Co., Ltd was founded in 1945 and is based in Seoul, South Korea.
Stock analysis
Sam-A Pharm. Co. Ltd (009300) currently trades at 12,990 KRW, while our model-based Fair Value estimate is 23,291 KRW, implying the stock looks roughly 44% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of 36,246 KRW per share, and 22 of the 24 models we run sit above the 12,990 KRW price.
Bear case: the Dividend Discount group reads lowest at 7,678 KRW, and 2 of the 24 models stay below the price. Data coverage for this calculation is medium.
Scenario range: 16,249 KRW (bear) to 31,637 KRW (bull), the price of 12,990 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 58/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Sam-A Pharm. Co. Ltd reported revenue of 77.8B KRW in FY2025 versus 54.7B KRW in FY2021, a compound +9.2%/yr. Reported net income was 12.9B KRW in FY2025, compounding +39.8%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.
Key figures
Market cap 79.3B KRW (≈ $58.6M) Micro · P/S ratio 1.11 · Dividend yield 5.0% · Net margin 14.6% · Return on equity 890% · Return on assets (EBIT) 7.3% (5-year average) · Operating margin 22.7% · Revenue (TTM) 75.5B KRW.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 64 out of 100 (low confidence).
What moves the price
The share trades about 22% below its 52-week high and 7% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −16% fair-value upside, at 79%, 009300 screens cheaper than that median.
Fair Value models
Bear16,249 KRWFair Value 23,291 KRWBull31,637 KRW
Price 12,990 KRW · Upside +79.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.71/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−18.6%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.7%
Start year 2020 (pandemic). Over 10 years: +2.7% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in KRW ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in KRW: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
≈ +35.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year≈ +30.7%
Dividend (yield on the price)5.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.base effect: 30.7% / 2.7%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.7% → 14%
⚠ Base effect: the rate starts in the earnings trough around 2020 (starting value 556 per share, median 1442 in 2016 to 2018). It measures the recovery from the trough, not lasting growth.
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−34.5%
The company could shrink this much every year for the next five years and today's price would still be justified.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −35.8% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Pharmaceuticals · 54 stocks
Beats the industry median on 12/12 measures
Overall it ranks above its industry peers.
Valuation
Quality Score58 · Above median
Fair Value upside+79.3% · Top 25%
Profitability
Return on assets5.2% · Above median
Net margin (12 months)14.6% · Top 25%
Operating margin (12 months)22.7% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)76.2% · Top 25%
Dividend yield (12 months)5.0% · Top 25%
Balance sheet
Debt / equity0.01× · Below median
Valuation Multiplesvs Pharmaceuticals median · lower = cheaper
P/B0.35× · Cheapest 25%
P/S (12 months)1.05× · Cheaper than median
Price / free cash flow (fiscal year)8.9× · Cheaper than median
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Sam-A Pharm. Co. Ltd (009300) overvalued or undervalued?
As of Nov 9, 2026, our model estimates a fair value of 23,291 KRW versus a price of 12,990 KRW, about +79% upside (undervalued).
What is the fair value of 009300?
Our model-based fair value for Sam-A Pharm. Co. Ltd is 23,291 KRW (as of Nov 9, 2026), built from audited fundamentals. The current price: 12,990 KRW.
What is the quality score of 009300?
Sam-A Pharm. Co. Ltd has a Quality Score of 58/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sam-A Pharm. Co. Ltd (009300)?
Our model-based price target is the fair value of 23,291 KRW (as of Nov 9, 2026) from 24 valuation models. Cautious scenario 16,249 KRW, optimistic scenario 31,637 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Sam-A Pharm. Co. Ltd stock forecast for 2026?
Our models put fair value at 23,291 KRW, about +79% upside versus a price of 12,990 KRW (undervalued). Cautious scenario 16,249 KRW, optimistic scenario 31,637 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Sam-A Pharm. Co. Ltd (009300)?
Sam-A Pharm. Co. Ltd reported trailing-twelve-month revenue of about 75.5B KRW (latest available figure, as of Nov 9, 2026).
Does Sam-A Pharm. Co. Ltd pay a dividend?
Sam-A Pharm. Co. Ltd currently shows a dividend yield of 4.99% relative to its recent price (as of Nov 9, 2026).
How much is the dividend of Sam-A Pharm. Co. Ltd (009300)?
Sam-A Pharm. Co. Ltd has a dividend yield of 5.0%. A dividend has been paid every year since at least 2000. Our assessment: Safety not assessed. Payout ratio and cash coverage are not available, so we do not judge how safe this dividend is.
What growth is priced into Sam-A Pharm. Co. Ltd (009300)?
For today's price to be fair in a discounted-cash-flow model, Sam-A Pharm. Co. Ltd would have to grow free cash flow by -34.5 % per year for five years (discount rate 11.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.7 % per year. As of Nov 9, 2026.
What discount rate (WACC) does the fair value of 009300 use?
Our models discount Sam-A Pharm. Co. Ltd at 11.9 %: a base by market capitalisation (micro), damped by beta 0.62, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Sam-A Pharm. Co. Ltd that is -34.5 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (11.9 %) and the same formula as our fair value.
How much growth has Sam-A Pharm. Co. Ltd (009300) delivered so far?
Over the past 5 years revenue at Sam-A Pharm. Co. Ltd grew +7.7 % a year. The price currently implies free-cash-flow growth of -34.5 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Sam-A Pharm. Co. Ltd (009300) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Sam-A Pharm. Co. Ltd (-34.5 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Sam-A Pharm. Co. Ltd (009300)?
The free-cash-flow yield on the price is 11.28 %: that much free cash flow Sam-A Pharm. Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (11.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Sam-A Pharm. Co. Ltd (009300)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sam-A Pharm. Co. Ltd it is 23,291 KRW per share (as of Nov 9, 2026), against a price of 12,990 KRW. It is the blended result of 24 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Sam-A Pharm. Co. Ltd stock overvalued or undervalued in 2026?
As of Nov 9, 2026, 009300 trades below its calculated fair value: price 12,990 KRW, fair value 23,291 KRW, a gap of about +79% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 009300?
No. The price is what the market pays today (12,990 KRW); the fair value is what the company's own numbers justify (23,291 KRW). For Sam-A Pharm. Co. Ltd the two are 10,301 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Sam-A Pharm. Co. Ltd worth?
The market values Sam-A Pharm. Co. Ltd at about 79.3B KRW (market capitalisation, as of Nov 9, 2026). Per share that is 12,990 KRW; our models calculate a fair value of 23,291 KRW per share.
What do the bullish and bearish scenarios say about 009300?
Our models span a range for Sam-A Pharm. Co. Ltd: cautious scenario 16,249 KRW, base 23,291 KRW, optimistic 31,637 KRW per share (as of Nov 9, 2026, price 12,990 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sam-A Pharm. Co. Ltd (009300)?
Balance-sheet figures for Sam-A Pharm. Co. Ltd (as of Nov 9, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 58/100, which measures business quality independently of the share price.
How far is 009300 from its 52-week high?
Sam-A Pharm. Co. Ltd trades at 12,990 KRW, about 22% below its 52-week high of 16,600 KRW and 7% above the low of 12,130 KRW (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of 23,291 KRW is for.
Which stocks are comparable to Sam-A Pharm. Co. Ltd?
From the same area (Healthcare) we also value ST Pharm Co, Caregen Co, Oscotec Inc, DongKook Pharmaceutical Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sam-A Pharm. Co. Ltd stock attractive at the current price?
The data as of Nov 9, 2026: price 12,990 KRW, calculated fair value 23,291 KRW (+79%), Quality Score 58/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 009300 calculated?
We run Sam-A Pharm. Co. Ltd through 24 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of 23,291 KRW builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Sam-A Pharm. Co. Ltd currently trades 44% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Sam-A Pharm. Co. Ltd (009300)?
The closing price on Nov 6, 2026 was 12,990 KRW. Our model-based fair value is 23,291 KRW, about +79% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Sam-A Pharm. Co. Ltd right now?
The price is below even our cautious bear case (16,249 KRW). The market is more pessimistic than our downside scenario. Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (16,249 KRW to 31,637 KRW) leaves room in how you read the outcome.
Key figures of Sam-A Pharm. Co. Ltd
How large is the market capitalisation of Sam-A Pharm. Co. Ltd (009300)?
The market capitalisation of Sam-A Pharm. Co. Ltd is 79.3B KRW (≈ $58.6M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sam-A Pharm. Co. Ltd (009300)?
The price-to-sales ratio of Sam-A Pharm. Co. Ltd is 1.11 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the dividend yield of Sam-A Pharm. Co. Ltd (009300)?
The dividend yield of Sam-A Pharm. Co. Ltd is 5.0%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sam-A Pharm. Co. Ltd (009300)?
The net margin of Sam-A Pharm. Co. Ltd is 14.6% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sam-A Pharm. Co. Ltd (009300)?
The return on equity (ROE) of Sam-A Pharm. Co. Ltd is 890% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sam-A Pharm. Co. Ltd (009300)?
On an EBIT basis the return on assets of Sam-A Pharm. Co. Ltd is 7.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sam-A Pharm. Co. Ltd (009300)?
The operating margin of Sam-A Pharm. Co. Ltd is 22.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sam-A Pharm. Co. Ltd (009300)?
Revenue at Sam-A Pharm. Co. Ltd is growing +76.2% versus a year earlier (3y avg −1.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sam-A Pharm. Co. Ltd (009300)?
Earnings per share at Sam-A Pharm. Co. Ltd are growing +569% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Sam-A Pharm. Co. Ltd in the live analysis
One click puts Sam-A Pharm. Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 9, 2026